KLOW blend dosage and evidence

What is KLOW blend?

How does KLOW blend work?

Assumed to be the four parts added together, and assumed is the key word. GHK-Cu carries copper into tissue. In lab dishes and in rat wound chambers, it drove the making of collagen and other skin building materials. KPV is the tail end of a skin hormone called alpha-MSH. In gut lining and immune cells in a dish, it blocks inflammation signals. BPC-157 and TB-500 work through the repair pathways on their own pages. No paper describes what these four do in the same syringe. Nobody knows if the effects add up, overlap or get in each other's way. And nobody knows if an acidic copper mix stays compatible with three other peptides over the weeks a vial sits in the fridge.

What have studies in people found about KLOW blend?

None for the mix, and no registered study of it. Below is the human record for each part, gathered in one place. It is thinner, and more about creams and gels, than any seller's page suggests.

• The mix: zero studies in people or animals. ClinicalTrials.gov lists no study of KLOW, or of any mix of GHK-Cu, KPV, BPC-157 and TB-500.
• GHK-Cu: the biggest reports come from hair clinics in Japan and India, where scalp injections that included copper peptide, given alongside other hair treatments, were followed by less hair loss. On its own, a GHK-Cu gel helped diabetic foot ulcers close, while a small study after laser treatment saw no visible difference. A new study of GHK-Cu gel on small wounds in about 60 healthy adults (NCT07437586) is under way. No published study has injected GHK-Cu by itself into people.
• BPC-157: the FDA's July 2026 review counted five human studies with fewer than 110 people in total. Two were only short conference summaries. None gave it for longer than two weeks, and none used the under-the-skin shots buyers use. A 2025 review of 36 studies found 35 were in animals or cells, and it found no safety data from people.
• TB-500: no human study by any route. A drug testing lab found the product is Ac-LKKTETQ, a seven building block fragment. The parent protein, thymosin beta 4, does have human trials. In a 9 patient eye drop study in severe dry eye, it cut eye discomfort 35.1% and damage on the eye's surface 59.1% compared with plain drops at day 56. Eye drops, of a different molecule, in nine people.
• KPV: no human data of any kind, by any route. ClinicalTrials.gov lists zero studies. The record is mouse gut inflammation, cells in a dish, and a 2019 skin review that calls these peptides future candidates rather than reporting a trial.

What this does not tell you: A mix cannot borrow the evidence of its parts, and here the parts have little to lend. The GHK-Cu human data is mostly creams and gels, and in the small laser study the measures taken by outside observers showed no difference. The KPV human data does not exist. The BPC-157 human data is five small studies by routes nobody uses. The TB-500 human data is about a different molecule. None of this says what four peptides do together, at a ratio the buyer did not choose, over the months people actually use these vials. Nobody has ever described the side effects of the mix, and nobody has ever measured blood copper in a person injecting it.

What do people who took KLOW blend report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Less joint and tendon pain in the first few weeks, described the same way people describe BPC-157 on its own.
• Gut symptoms settling, which users credit to the KPV.
• Skin and hair looking better, credited to the copper peptide.
• Stinging, redness or lumps where the needle went in. This is reported more often than with single peptides and usually blamed on how acidic the copper solution is.
• Skin or gum darkening in a small number of reports. That matches what the FDA's side effect records describe for an injected BPC-157 and TB-500 product.
• No effect at all. This is a common report, and rarely the one that gets reposted.
• Ongoing arguments about dosing, because the seller fixes the ratio and none of the four parts has an established human dose.

Sources: Peptide and bodybuilding forums including r/peptides, clinic write-ups and vendor testimonial pages. These are uncontrolled self-reports, usually from people running other things at the same time, frequently including a topical copper serum. They are recorded here as reports and are not evidence of effect. The FDA side-effect material referenced above comes from the agency's 2026 BPC-157 evaluation cited on this page.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2006
  Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

  After laser treatment around the mouth, 13 people used aftercare creams with or without GHK-Cu. Redness faded and wrinkles improved the same either way. The people using GHK-Cu rated their skin better.

  13 people after laser treatment around the mouth, aftercare creams with or without GHK-Cu for 12 weeks. Redness faded at the same speed and wrinkles and skin quality improved the same amount either way. On their own questionnaire, the GHK-Cu group rated their skin better.

  PMID 16847171 Archives of Facial Plastic Surgery
• Study in people2026
  Topical GHK-Cu Gel for Acute Skin Wound Healing

  The first real trial of GHK-Cu is running and has not reported. It plans to give 60 healthy adults two small punched wounds each, treating one with GHK-Cu gel and the other with an identical gel without it. That is a strong design, because every person acts as their own comparison. Note what it tests. A gel on skin, not the injected blends sold online.

  A recruiting phase 2 trial, estimated 60 healthy adults, giving each participant two punch-biopsy wounds and randomising each wound to GHK-Cu gel or a matching vehicle gel. Started February 2026, has not reported. It is the only registered interventional trial of GHK-Cu, and it is a gel applied to skin, not an injected blend.

  NCT07437586 ClinicalTrials.gov
• Review of studies2018
  Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

  A review of GHK-Cu lab data: collagen and elastin building, support for skin cells, and calming inflammation. All of it is creams or dish work. None of it is an injected four-peptide mix, and none of it sets a dose.

  Pickart and Margolina review the gene and cell data behind GHK-Cu: collagen and elastin synthesis, fibroblast support and anti-inflammatory signalling. All of it is topical or in vitro, none of it is an injected four-peptide blend, and none of it establishes a dose for one.

  PMID 29986520 International Journal of Molecular Sciences
• Review of studies2019
  Are melanocortin peptides future therapeutics for cutaneous wound healing?

  A skin review. It describes KPV as a short piece of a skin hormone that keeps the anti-inflammatory action without darkening skin. It suggests peptides like this as future options for wounds. The work it covers is computer, dish and animal studies. No human study of KPV is registered.

  A dermatology review describing KPV as a truncated alpha-MSH peptide that keeps the anti-inflammatory activity without the pigment-inducing activity, and proposing peptides of this kind as future candidates for cutaneous wounds and skin ulcers. The experimental approaches it outlines are in silico, in vitro, ex vivo and animal. Future candidate is the accurate description: ClinicalTrials.gov returns no registered study of KPV in people.

  PMID 30661264 Experimental Dermatology
• Review of studies2010
  An exposure-response curve for copper excess and deficiency

  A review of copper research. For copper you swallow, it puts the best intake at 2.6 mg a day, the US daily guide at 0.9 mg and the upper limit at 10 mg. It says nothing about injected copper peptides.

  Categorical regression across the copper literature estimates an optimal oral intake of 2.6 mg a day, against a US recommended dietary intake of 0.9 mg a day and a tolerable upper intake level of 10 mg a day. Every number here is for copper taken by mouth, where absorption is regulated in the gut. The paper says nothing about injected copper peptides, and no equivalent analysis exists for that route.

  PMID 21170809 Journal of Toxicology and Environmental Health, Part B
• Review of studies2024
  Is Copper Still Safe for Us? What Do We Know and What Are the Latest Literature Statements?

  A 2024 review of copper safety. Your whole body holds 50 to 120 mg of copper, and the safe upper intake is 10 to 12 mg a day. It warns that even small changes in copper can be toxic. It covers copper from food and the environment, not injected peptides.

  Total body copper is 50 to 120 mg, the upper limit of normal serum copper in healthy adults is about 1.5 mg/L, the safe upper limit of average intake is set at 10 to 12 mg a day against a reference limit of 0.9 mg a day, and the biological half-life from diet runs 13 to 33 days. The review notes that even small changes in copper concentration can carry significant toxicity. That is the scale against which a vial holding about 7.9 mg of elemental copper should be read, with the caveat that the review covers dietary and environmental copper rather than an injected peptide complex.

  PMID 39194715 Current Issues in Molecular Biology
• Review of studies2018
  Wilson disease

  A review of Wilson disease, an inherited problem where copper builds up in the liver, brain and other organs. It is the clearest reason a copper-loaded vial is not harmless. The people most at risk can be found with a gene test and a blood test most buyers have never had.

  An inherited defect in ATP7B, the copper-transporting ATPase, causes pathological copper accumulation in liver, brain and other organs, treated with chelation or zinc salts and in selected cases transplant. This is the clearest reason a copper-loaded vial is not a neutral product: the people it would harm most are identified by a genetic test and a ceruloplasmin level that most buyers have never had.

  PMID 30190489 Nature Reviews Disease Primers
• Review of studies2026
  FDA briefing document on BPC-157 for the July 2026 PCAC meeting

  The FDA's 2026 review of BPC-157. It counted five human studies with fewer than 110 people. None gave it for more than two weeks, and none used shots under the skin. Staff found no adequate human data and mislabelled products for sale.

  FDA's evaluation counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, with no study running longer than two weeks of dosing and none administering the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.

  Source FDA
• Animal study2008
  Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

  In mice with gut inflammation. KPV given alone led to faster recovery, more weight regained and less inflammation in the colon. Nothing here tests KPV in a mix or in people.

  In two mouse colitis models KPV led to earlier recovery, greater body-weight regain, fewer inflammatory infiltrates and lower myeloperoxidase activity in colon tissue. Mouse gut inflammation with KPV given alone; nothing here tests KPV in a blend or in people.

  PMID 18092346 Inflammatory Bowel Diseases
• Lab (cells in a dish)2012
  Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential

  In a lab. A drug testing lab found that TB-500 is a seven building block piece of thymosin beta 4, not the full 43 building block protein. So one of the four parts in this mix is not the molecule its marketing names.

  A doping control laboratory analysed the TB-500 formulation by high performance liquid chromatography and high resolution mass spectrometry and identified its contents as Ac-LKKTETQ, the N-terminal acetylated 17 to 23 fragment of human thymosin beta 4. Seven amino acids, not the 43 amino acid protein. One quarter of this blend by component count is therefore not the molecule its marketing names.

  PMID 22962027 Drug Testing and Analysis